Deep Phenotyping of the Renal Allograft to Prognosticate Clinical Outcomes
Launched by UNIVERSITY OF PITTSBURGH · May 26, 2024
Trial Information
Current as of February 08, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This study is exploratory in nature and aims to elucidate the phenotypic, transcriptional, and epigenetic underpinnings of renal transplant rejection. The study is designed to provide improved understanding of the regulation of intra-graft alloimmune response in the renal transplant recipients.
In this single center, prospective, longitudinal, observational cohort study, sequential assessment of renal biopsies will be performed at baseline (pre-implantation), 3 months and at one-year post-transplantation in addition to any for-cause biopsies within the first five years post-transplantation...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. All adult living or deceased donor renal transplant recipients (age ≥ 18 years), irrespective of gender, race, or ethnic background.
- • 2. Able to understand and provide inform consent.
- Exclusion Criteria:
- • 1. Medical contraindications to undergo renal biopsy (use of long-term anticoagulation, low platelet count of \<100,000/uL)
- • 2. Cause of ESRD likely to recur in transplant: Hemolytic uremic syndrome (HUS)
- • 3. Not maintained on standard of care immunosuppression therapy (Thymoglobulin induction followed by tacrolimus and mycophenolate maintenance)
Trial Officials
Aravind Cherukuri, MD
Principal Investigator
University of Pittsburgh
About University Of Pittsburgh
The University of Pittsburgh is a leading research institution known for its commitment to advancing medical science and improving patient care through innovative clinical trials. With a robust infrastructure for research and a multidisciplinary approach, the university fosters collaboration among experts in various fields, facilitating the development of novel therapies and interventions. Its clinical trial programs emphasize ethical standards, patient safety, and the integration of cutting-edge technology, making the University of Pittsburgh a pivotal contributor to the landscape of clinical research and a trusted partner in the pursuit of health advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pittsburgh, Pennsylvania, United States
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0